Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21606215 | 0.79 | NOS1 (0.33) | NOS1TDO2ACHE | |
| SCHEMBL22472907 | 0.77 | ELANE (0.36) | ACHE | |
| SCHEMBL15703055 | 0.76 | NOS1 (0.36) | NOS1TDO2ACHE | |
| SCHEMBL179278 | 0.75 | — | — | |
| SCHEMBL26775544 | 0.73 | — | — | |
| SCHEMBL14964517 | 0.71 | JAK2 (0.30) | — | |
| SCHEMBL24023949 | 0.71 | — | — | |
| SCHEMBL22083524 | 0.71 | — | — | |
| SCHEMBL15703086 | 0.70 | ACHE (0.50) | NOS1ACHE | |
| SCHEMBL2766077 | 0.70 | NOS1 (0.35) | NOS1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773090-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | NOS1 888/4885TDO2 2134/4885ACHE 82/4885 |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | NOS1 888/4885TDO2 2134/4885ACHE 82/4885 |
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | NOS1 888/4885TDO2 2134/4885ACHE 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.